Research use only · Not for human consumptionPepwizard compares vendor pricing for research-grade compounds. Nothing on this site is medical advice. How we price.
Compound sheet
Fat Loss / Oral GLP-1
07.05.2026
FAT LOSSResearch-onlyInvestigationalLow availability
Orforglipron
Oral GLP-1 · aka "LY3502970"
“Small-molecule GLP-1. Ends the injection monopoly.”
No offers tracked yet.
§ 01 — Spec
Amino acids
—
Half-life
~25 hours
Admin
Oral
Typical dose
12–36 mg oral once daily (in trials)
Live offers
0
§ 02 — Abstract
Eli Lilly's oral, non-peptide GLP-1 receptor agonist. The first viable once-daily pill competing with injectable semaglutide and tirzepatide. Expected FDA approval in 2026–2027.
Orforglipron is a small molecule (not a peptide) that mimics GLP-1 binding. Its oral bioavailability is the breakthrough — no injection, no cold-chain storage, no complex dosing schedule.
Studied for
01Weight loss comparable to injectable GLP-1s (~14–15% in Phase 3)
02Once-daily oral dosing
03No injection infrastructure needed
04Broader accessibility
§ Codes
Live coupon for Orforglipron.
§ 03 — Stock
No approved vendor stocks Orforglipron yet.
We only feature vendors whose affiliate programmes we've signed off — no inventory padding. We're onboarding more partners and will list Orforglipron as soon as one stocks it.
Email me when it lists
We'll ping you the moment a tracked vendor lists Orforglipron.
Free · weekly
Your email. That's it. No account. No tracking pixels. Unsubscribe anytime.
§ 04 — Trend
Tracking begins.
We started tracking Orforglipron on 2026-05-07. The chart unlocks at 14 daily snapshots — currently 1 on file.
1 snapshot · floor on 07.05.2026